BioNTech SE
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BNTXN.MX | GMAB | ROIV | 688382.SS | 1877.HK | 6IB.F | |
|---|---|---|---|---|---|---|
| Market cap | 423.96B | 33.89B | 27.61B | 8.38B | 16.34B | 17.27B |
| P/E (TTM) | — | 43.4 | — | — | — | 123.8 |
| Forward P/E | — | 34.9 | -27.5 | -43.8 | 66.7 | — |
| Price/book | 1.1 | 5.5 | 6.5 | 6.6 | 2.4 | 6.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −9.75% | +91.12% | +85.85% | −48.70% | −39.19% | −1.76% |
| Today | 0.00% | −0.72% | +6.08% | +4.33% | +1.53% | +3.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All BNTXN.MX news ›BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
BioNTech earns a Hold rating as cash burn, pipeline narrowing, and two-asset concentration raise risk. Click here to read an analysis of BNTX stock now. - BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance…
Emvena Therapeutics Receives Investment From Penn-BioNTech Innovative Therapeutics Seed Fund
FinSMEs Emvena Therapeutics Receives Investment From Penn-BioNTech Innovative Therapeutics Seed Fund Emvena Therapeutics, a Philadelphia, PA-based biotechnology company developing mRNA medicines designed to
BioNTech (NASDAQ:BNTX) Price Target Cut to $125.00 by Analysts at UBS Group
Posted by Mitch Edgeman on Nov 4th, 2026 BioNTech (NASDAQ:BNTX – Get Free Report) had its target price decreased by analysts at UBS Group from $135.00 to $125.00 in a research report issued on Wednesday, Benzinga reports. The firm…
BioNTech outlines 2026 revenue guidance of €1.7B-€1.9B as it anticipates gotistobart interim analysis before year-end
BioNTech Q3 2026 earnings: raised revenue guidance, oncology pipeline progress, and key trial risks. Earnings Call Insights: BioNTech (BNTX) Q3 2026 CEO Ugur Sahin said, “We have made good progress against our strategic milestones set out…
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Douglas Maffei - Vice President of Strategy & Investor RelationsUgur Sahin - Co-Founder, CEO & Chair of the Management BoardÖzlem Türeci - Co-Founder, Chief Medical…
After mRNA Trial Setbacks, BioNTech Still Pushing Ahead in Cancer
Despite Trial Misses, BioNTech Keeps Focused on mRNA Cancer Therapies GenomeWeb Despite Trial Misses, BioNTech Keeps Focused on mRNA Cancer Therapies
BioNTech: Higher FY revenue guidance and advancing oncology trials offset pipeline and demand uncertainties
TradingView BioNTech: Higher FY revenue guidance and advancing oncology trials offset pipeline and demand uncertainties Q3 revenue declined as COVID-19 vaccine demand fell, but stronger partn
J.P. Morgan Sticks to Their Hold Rating for BioNTech SE (BNTX)
J.P. Morgan analyst Jessica Fye maintained a Hold rating on BioNTech SE today and set a price target of $86.86. According to TipRanks, Fye is a 4-star analyst with an average return of 4.1% and a 52.20% success rate. Fye covers the…
BioNTech reports Q3 2026 revenues of €1.29B, advances oncology pipeline, raises 2026 revenue guidance
BioNTech announced its third quarter 2026 financial results with revenues of €1.29 billion, driven by ongoing COVID-19 vaccine sales despite lower demand. The company highlighted progress in its oncology pipeline, including new Phase 3…
BioNTech to test pumitamig-Trodelvy breast cancer combo
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com17
- markets.businessinsider.com9
- 247wallst.com8
- themarketsdaily.com6
- stocktitan.net5
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 76 articles, not a forecast.